IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2370
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$549M
Richard A. Miller
Corvus Pharmaceuticals, Inc. focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company was incorporated in 2014 and is based in Burlingame, California.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CRVS Corvus Pharmaceuticals, Inc. | 48 | 23 | 39 | 95 | - | - | -60.2% | -53.7% | - | - | - | - | 0.0% | 12.0x | $549M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Corvus Pharmaceuticals, Inc. (CRVS) receives a "Reduce" rating with a composite score of 47.7/100. It ranks #2370 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Outperforming peers — winners tend to keep winning over 3-12 months
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for CRVS.
View All RatingsROE proxy -60.2% (sector -1.9%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover N/A
Rev growth N/A, 10yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Corvus Pharmaceuticals, Inc. (CRVS) as a Reduce with a composite score of 47.7/100 at a current price of $17.82. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
Corvus Pharmaceuticals, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 47.7/100 places it at rank #2370 in our full universe.
No Moat
Medium
Poor
Fair Value
Positive momentum indicates institutional accumulation.
Stable competitive position in a defensive sector.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
Corvus Pharmaceuticals, Inc. represents a reduce based on multi-factor quantitative performance.
Corvus Pharmaceuticals, Inc. receives a Reduce rating from our analysis, with a composite score of 47.7/100 and 2 out of 5 stars, ranking #2370 out of 7,333 stocks. CRVS's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
Corvus Pharmaceuticals, Inc. registers a weak quality score of just 23/100, indicating significant profitability challenges. The company reports a return on equity of -60.2% (sector avg: -1.9%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
With a value score of 39/100, CRVS appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 19.34x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Corvus Pharmaceuticals, Inc.'s investment score of 21/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -53.7% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Corvus Pharmaceuticals, Inc. (CRVS) is exhibiting exceptional momentum with a score of 95/100, placing it among the strongest trending stocks in the market. Revenue growth data is not currently available, while a beta of -0.06 reflects its sensitivity to broader market moves. Stocks with momentum scores this high have historically outperformed over the following 3–12 months, suggesting CRVS may continue to benefit from strong institutional interest and positive price trends.
CRVS's stability score of 41/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of -0.06 and a debt-to-equity ratio of 12.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 53/100 for CRVS suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 12.00x), small-cap liquidity risk. With a $549M market cap (small-cap), Corvus Pharmaceuticals, Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
Corvus Pharmaceuticals, Inc. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2370 of 7,333 overall (68th percentile). Key comparisons include ROE of -60.2% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While CRVS currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Investment (21) would have the largest impact on the composite score.
ROE 3066% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 5614% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Seven brokerages have given Corvus Pharmaceuticals (NASDAQ:CRVS) an average "Moderate Buy" rating, with six buy recommendations and one sell. The average 12-month price target is $31.80, with some analysts recently raising their targets. The stock opened at $18.66, trading above its 50-day and 200-day moving averages, and institutional investors now own about 46.64% of the company.
Corvus Pharmaceuticals (NASDAQ:CRVS) announced an upsized underwritten public offering of 7,900,677 shares at $22.15 per share, expecting to raise approximately $175 million in gross proceeds. The company, which has seen significant stock appreciation, plans to use the capital for working capital, general corporate purposes, including R&D, and ongoing clinical trials for T cell lymphoma and atopic dermatitis. Jefferies and Goldman Sachs are leading the offering, which is set to close around January 23.
Corvus Pharmaceuticals (NASDAQ:CRVS) saw a 9.3% decrease in its market value last week, causing dismay among both retail investors and institutions. Retail investors hold the largest share of ownership at 39%, while institutions also hold 39%. Private equity firms and hedge funds also have significant stakes, with the top 12 shareholders controlling 51% of the company, and no single shareholder holding a majority interest.
Corvus Pharmaceuticals (NASDAQ:CRVS) has received a "Moderate Buy" consensus rating from analysts, with four buy recommendations and one sell. The average 12-month price target is $14.25, significantly higher than its current trading price of $8.51. The company, a clinical-stage biopharma, recently reported quarterly earnings that beat estimates and institutional investors have been adjusting their holdings.
U.S. stock futures climbed on Wednesday as investors await the Federal Reserve's interest rate decision and economic data releases. The Dow Jones index extended its losing streak to nine consecutive sessions, the longest since 1978.